Abstract
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Daisuke Taguchi, Yohei Shirakami, Toshihide Maeda, Daisuke Minowa, Masaya Kubota, Hiroyasu Sakai, Hiroyuki Tomita, Masahito Shimizu
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
European association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
10.1016/j.jhep.2024.04.031 · 2024
Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis
10.1016/s2468-1253(19)30039-1 · 2019
Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2014 to 2018 in Japan: a large-scale multicenter retrospective study
10.1111/hepr.13947 · 2023
Usefulness of health checkup-based indices in identifying metabolic dysfunction-associated steatotic liver disease
10.1002/jgh3.13110 · 2024
Hepatic inflammation and fibrosis are profiles related to mid-term mortality in biopsy-proven MASLD: a multicenter study in Japan
10.1111/apt.17995 · 2024
Long-term clinical outcomes in steatotic liver disease and incidence of liver-related events, cardiovascular events and all-cause mortality
10.1111/apt.18015 · 2024
Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020
10.1007/s00535-021-01796-x · 2021
Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020
10.1111/hepr.13688 · 2021
The effectiveness and acceptability of Mediterranean diet and calorie restriction in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis
10.1016/j.clnu.2022.06.037 · 2022
Usefulness of a questionnaire for assessing the relationship between eating behavior and steatotic liver disease among Japanese male young adults
10.1038/s41598-024-52797-8 · 2024
Metabolic dysfunction-associated steatotic liver disease and the gut microbiome: pathogenic insights and therapeutic innovations
10.1172/jci186423 · 2025
NLRP3 inflammasome in hepatic diseases: a pharmacological target
10.1016/j.bcp.2023.115861 · 2023
Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells
10.1002/hep.24341 · 2011
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
10.1038/nature10809 · 2012
Lack of NLRP3-inflammasome leads to gut-liver axis derangement, gut dysbiosis and a worsened phenotype in a mouse model of NAFLD
2017
NLRP3 deficiency did not attenuate NASH development under high fat calorie diet plus high fructose and glucose in drinking water
10.1038/s41374-021-00535-3 · 2021
Genetic deletion or pharmacologic inhibition of the Nlrp3 inflammasome did not ameliorate experimental NASH
10.1016/j.jlr.2023.100330 · 2023
NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice
10.1016/j.jhep.2017.01.022 · 2017
NLRP3 deficiency reprograms hepatic glucose metabolism but fails to ameliorate hepatic inflammation and fibrosis in the MCD model
2026
An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis
10.1111/iep.12008 · 2013
Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology
10.1371/journal.pone.0115922 · 2014
Skeletal muscle atrophy is exacerbated by steatotic and fibrotic liver-derived TNF-α in senescence-accelerated mice
10.1111/jgh.16171 · 2023
Inhibitory effects of a selective prostaglandin E2 receptor antagonist RQ-15986 on inflammation-related colon tumorigenesis in APC-mutant rats
10.1371/journal.pone.0251942 · 2021
Inhibitory effects of astaxanthin on azoxymethane-induced colonic preneoplastic lesions in C57/BL/KsJ-db/db mice
10.1186/s12876-014-0212-z · 2014
Liver acid sphingomyelinase inhibits growth of metastatic colon cancer
2013
ASK1 inhibition reduces cell death and hepatic fibrosis in an Nlrp3 mutant liver injury model
10.1172/jci.insight.123294 · 2020
NOD-like receptor protein 3 activation causes spontaneous inflammation and fibrosis that mimics human NASH
10.1002/hep.32320 · 2022
Cell-specific deletion of NLRP3 inflammasome identifies myeloid cells as key drivers of liver inflammation and fibrosis in Murine steatohepatitis
10.1016/j.jcmgh.2022.06.007 · 2022
NLRP3 deletion inhibits the non-alcoholic steatohepatitis development and inflammation in kupffer cells induced by palmitic acid
10.1007/s10753-017-0628-z · 2017
An overview of the non-canonical inflammasome
10.1016/j.mam.2020.100924 · 2020
Matrix metalloproteinases induce extracellular matrix degradation through various pathways to alleviate hepatic fibrosis
10.1016/j.biopha.2023.114472 · 2023
Inflammasome activation and function in liver disease
10.1038/nrgastro.2015.94 · 2015
Inflammasomes and fibrosis
2021
No additional external references are available.